Adient price target raised to $32 from $30 at UBS

UBS raised the firm’s price target on Adient (ADNT) to $32 from $30 and keeps a Buy rating on the shares. A growth inflection is on the horizon following the Q1 beat and raise, the analyst tells investors in a research note.